Memory loss is not just only the symptom of neurodegenerative diseases like dementia. Dementia is one of the most common issues all around the world and is found to be linked with the age-related factor or health issues like depression.
The recent research by the researchers from the Toronto’s Center for Addiction and Mental Health in Canada supports the use of a new compound in order to reverse this psychological effect. Memory loss is not just because of dementia but is also highly linked with a natural process that is aging.
Memory issues likewise happen in individuals who continuously encounter emotional distress, especially the people who are confronting health issues that may incorporate depression. For example, as per the research presented over a year ago in the Journal Neurology, individuals who were displaying observable side effects of depression additionally had poor long past memory. It is a type of memory which holds the ability to recall special events.
Recently, researchers from Toronto’s Center for Addiction and Mental Health in Canada have been working day and night to develop such compounds which can easily reverse the memory loss; one of the common manifestation of aging and depression.
Dr. Etienne Sibille a study author said: “Currently, there are no medications to treat cognitive symptoms such as memory loss that occur in depression, other mental illnesses, and aging.” However, the preclinical trial shows that the new compound promises for the rapid recovery of memory loss. The researchers also noted that the new compound also proved to be successful in fixing the underlying cause of this.
Dr. Sibille and his team members directed a series of researches in order to reach an appropriate compound for the problem. The researchers published their findings in the Journal of Molecular Neuropsychiatry. The group additionally displayed their work at the American Association for the Advancement of Science Annual Meeting in Washington, DC.
Focusing on the defective system
In the main phase of their research, Dr. Sibille and other members scanned for and found the interruptions to brain cell receptors in the GABA synapse system. Past research has intensely ensnared the GABA system in mental health issues, for example, depression and nervousness. The system additionally controls the correspondence between certain brain cells and their action.
Presently, the researchers believe that impairments in the receptors of the GABA system likewise also cause memory loss associated with depression and progression of age. In their research, the researchers built up a progression of molecules with the target of binding and activating the flawed receptors. The researchers think that by doing so, this will improve the memory loss symptoms as it will help in fixing the underlying issue.
These new compounds are an advanced version of benzodiazepines. It is classified as a sedative drug which doctors usually use for treating the problem of anxiety and activates the GABA neurotransmitter system.
The preclinical trial was carried on rodents who were going through memory loss due to stress. Researchers made these mice have a single dose of this new surprising compound. Within 30 minutes it was quite shocking for the team to observe the memory functioning back to normal. The researchers saw this result after repeating the procedure at least 15 times.
Repairing the baseline mechanism and enhancing memory
At another stage, the specialists worked with preclinical models of age-related memory impairments. In these cases as well the researchers observed the same positive effect. Additionally, in this circumstance, the models’ physiological performance increased to 80 percent, which is linked with young and early-grown-up brains. If the compound is given on daily basis, the positive effects of the compound can last more than 2 months.
Dr. Etienne Sibille said: “The aged cells re-grew to appear the same as young brain cells, showing that our novel molecules can modify the brain in addition to improving symptoms.” The team believes that in these next 2 years they will be able to carry out the clinical trial on human participants and test the efficacy and safety of the compound.
“We’ve shown that our molecules enter the brain, are safe, activate the target cells, and reverse the cognitive deficit of memory loss,” the researcher says. The group likewise takes note that the molecules are an essential step forward, as their applications will probably be wide, grasping physiological issues linked with mental health conditions through to the memory loss that happens in the early stage of Alzheimer’s disease.